

Pembrolizumab KEYNOTE-355

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



No QoL benefit



Serious and disabling adverse effects



Other adjustments



Pembrolizumab KEYNOTE-355

FINAL SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Treatment of locally recurrent unresectable or metastatic TNBC in adults whose tumours express PD-L1 with a CPS  $\geq 10$  and who have not received prior chemotherapy  
Experimental Arm: Pembrolizumab + ChT  
Control Arm: Placebo plus ChT

